EUVIMEDОткрийте EUVIMED
CrossrefИнфокарта

Boosting the Therapeutic Potential of Extracellular Vesicles Derived From Mesenchymal Stem Cells via Advanced Preconditioning for Neurodegenerative Disorders

Cristina D’Arrigo, Sara Labbate, Denise Galante

Stem Cells International · 2025-01 · 2025 (1)

DOI: 10.1155/sci/2616653 ↗
РезюмеБиблиографски данни

Резюме

Acute and chronic neurodegenerative conditions (NDs) are major causes of disability and mortality worldwide. Acute NDs encompass conditions such as stroke, traumatic brain injury (TBI), and spinal cord injury (SCI). On the other hand, chronic NDs include Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS). Currently, no definitive cure exists for these diseases, and available therapies focus primarily on slowing the progression of symptoms. Mesenchymal stem cells (MSCs), due to their multilineage differentiation capacity, immunomodulatory abilities, and regenerative properties, have gained attention in regenerative medicine. In recent years, extracellular vesicles (EVs) derived from MSCs have shown great promise as a cell‐free therapeutic approach, eliminating the risks associated with direct MSCs use, such as tumorigenicity and poor cell survival after transplantation. EVs have emerged as powerful mediators of intercellular communication and tissue repair, exhibiting immunomodulatory, anti‐inflammatory, and proregenerative properties. However, limitations such as low EVs yield and reduced efficacy due to MSCs replicative senescence restrict their therapeutic potential. Preconditioning strategies, including hypoxia, 3D cultures, and biochemical priming, have been explored in other fields to enhance EVs properties, yet their specific application to NDs remains under‐reported. This review aims to address this gap by analyzing the preconditioning methods used to boost the therapeutic potential of MSCs‐derived EVs for neurodegenerative diseases. These preconditioning strategies may enhance EVs yield, functional cargo, and targeted therapeutic efficacy for treating acute and chronic NDs.

Знание, съобразено с Вашата работа.

От безплатното начало през личното търсене на литература до пълния Research Suite.

Виж тарифите →

Включени ли са всички издателски пълни текстове?

Не. Библиографските записи, резюметата и пълните текстове са различни видове съдържание. Дали е наличен пълен текст зависи от източника, Open Access и вашите съществуващи лицензи. План на EUVIMED не заменя допълнителни издателски права.

Виж тарифите →